Versantis is a clinical-stage company developing transformative orphan drugs that fill the medical gap in the critical care of liver and pediatric diseases. The company is now advancing its lead candidate, VS-01, into a Phase 2a trial which will lead to pivotal trials in two orphan indications.
Products, services, technology
VS-01 is a proprietary first-line treatment for acute liver diseases able to simultaneously support the failing liver, brain, and kidneys. VS-01 received orphan drug (FDA, EMA) and Rare Pediatric Disease designations (FDA) which help to streamline and value its clinical development pathway.